The Cancer Mutation D83V Induces an α-Helix to β-Strand Conformation Switch in MEF2B.

MEF2B is a major target of somatic mutations in non-Hodgkin lymphoma. Most of these mutations are non-synonymous substitutions of surface residues in the MADS-box/MEF2 domain. Among them, D83V is the most frequent mutation found in tumor cells. The link between this hotspot mutation and cancer is not well understood. Here we show that the D83V mutation induces a dramatic α-helix to β-strand switch in the MEF2 domain. Located in an α-helix region rich in β-branched residues, the D83V mutation not only removes the extensive helix stabilization interactions but also introduces an additional β-branched residue that further shifts the conformation equilibrium from α-helix to β-strand. Cross-database analyses of cancer mutations and chameleon sequences revealed a number of well-known cancer targets harboring β-strand favoring mutations in chameleon α-helices, suggesting a commonality of such conformational switch in certain cancers and a new factor to consider when stratifying the rapidly expanding cancer mutation data.

[1]  P. Alexander,et al.  A minimal sequence code for switching protein structure and function , 2009, Proceedings of the National Academy of Sciences.

[2]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[3]  M. Gearing,et al.  Regulation of Neuronal Survival Factor MEF2D by Chaperone-Mediated Autophagy , 2009, Science.

[4]  E. Olson,et al.  Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. , 2009, Blood.

[5]  Y. Kallberg,et al.  Prediction of Amyloid Fibril-forming Proteins* , 2001, The Journal of Biological Chemistry.

[6]  C Sander,et al.  On the use of sequence homologies to predict protein structure: identical pentapeptides can have completely different conformations. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Eric S. Lander,et al.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.

[8]  M. Grütter,et al.  Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. , 1998, Acta crystallographica. Section D, Biological crystallography.

[9]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[10]  H. Youn,et al.  Cabin1 represses MEF2-dependent Nur77 expression and T cell apoptosis by controlling association of histone deacetylases and acetylases with MEF2. , 2000, Immunity.

[11]  K. Webster,et al.  Control of Cardiac-specific Transcription by p300 through Myocyte Enhancer Factor-2D* , 2001, The Journal of Biological Chemistry.

[12]  Danielle Hulsman,et al.  Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice , 2002, Nature Genetics.

[13]  Alexei Vagin,et al.  Molecular replacement with MOLREP. , 2010, Acta crystallographica. Section D, Biological crystallography.

[14]  N. Copeland,et al.  Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. , 2005, Blood.

[15]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[16]  B. Black,et al.  Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins , 1995, Cell.

[17]  K. Basso,et al.  MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma , 2013, Nature Immunology.

[18]  K. Sakaguchi,et al.  Cancer-associated p53 Tetramerization Domain Mutants , 2010, The Journal of Biological Chemistry.

[19]  S. Hunger,et al.  Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia , 2005, Leukemia.

[20]  M. Marra,et al.  MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation , 2015, Nature Communications.

[21]  Y. Kallberg,et al.  Stabilization of discordant helices in amyloid fibril‐forming proteins , 2004, Protein science : a publication of the Protein Society.

[22]  R. Burgess Use of polyethyleneimine in purification of DNA-binding proteins. , 1991, Methods in enzymology.

[23]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[24]  F. Camargo,et al.  Regulation of lymphoid versus myeloid fate 'choice' by the transcription factor Mef2c , 2009, Nature Immunology.

[25]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[26]  V. Kiermer,et al.  HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. , 2003, Immunity.

[27]  Takeshi Suzuki,et al.  New genes involved in cancer identified by retroviral tagging , 2002, Nature Genetics.

[28]  J. Harper,et al.  A Calcium-Regulated MEF2 Sumoylation Switch Controls Postsynaptic Differentiation , 2006, Science.

[29]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[30]  E. Olson,et al.  MEF2: a calcium-dependent regulator of cell division, differentiation and death. , 2002, Trends in biochemical sciences.

[31]  F. Cosset,et al.  A Point Mutation in the N-Terminal Amphipathic Helix α0 in NS3 Promotes Hepatitis C Virus Assembly by Altering Core Localization to the Endoplasmic Reticulum and Facilitating Virus Budding , 2017, Journal of Virology.

[32]  Richard A. Moore,et al.  The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. , 2013, Blood.

[33]  J. Inazawa,et al.  Identification of a novel fusion gene in a pre‐B acute lymphoblastic leukemia with t(1;19)(q23;p13) , 2004, Cancer science.

[34]  Irina Artsimovitch,et al.  An α Helix to β Barrel Domain Switch Transforms the Transcription Factor RfaH into a Translation Factor , 2012, Cell.

[35]  N. Jayathilaka,et al.  Structure of the MADS-box/MEF2 domain of MEF2A bound to DNA and its implication for myocardin recruitment. , 2010, Journal of molecular biology.

[36]  E. Olson,et al.  MEF2: a central regulator of diverse developmental programs , 2007, Development.

[37]  Manel Juan,et al.  Landscape of somatic mutations and clonal evolution in mantle cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[38]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[39]  H. Drexler,et al.  MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines , 2008, Leukemia.

[40]  Andrey A Lebedev,et al.  Space-group and origin ambiguity in macromolecular structures with pseudo-symmetry and its treatment with the program Zanuda. , 2014, Acta crystallographica. Section D, Biological crystallography.

[41]  S. Hunger,et al.  Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute lymphoblastic leukemia , 2007, Leukemia.

[42]  E. Olson,et al.  MEF2 responds to multiple calcium‐regulated signals in the control of skeletal muscle fiber type , 2000, The EMBO journal.

[43]  P. Y. Chou,et al.  Prediction of protein conformation. , 1974, Biochemistry.

[44]  Philip R. Evans,et al.  An introduction to data reduction: space-group determination, scaling and intensity statistics , 2011, Acta crystallographica. Section D, Biological crystallography.

[45]  Song Tan,et al.  Crystal structure of the yeast MATα2/MCM1/DNA ternary complex , 1998, Nature.

[46]  Brian F. Volkman,et al.  Interconversion between two unrelated protein folds in the lymphotactin native state , 2008, Proceedings of the National Academy of Sciences.

[47]  E. Olson,et al.  Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. , 2000, Molecular cell.

[48]  Lin Chen,et al.  Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2 , 2003, Nature.

[49]  E. Miska,et al.  MEF‐2 function is modified by a novel co‐repressor, MITR , 1999, The EMBO journal.

[50]  Da-Zhi Wang,et al.  The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. , 2008, The Journal of clinical investigation.

[51]  Kohei Uosaki,et al.  Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. , 2006, Biochemistry.

[52]  Jun O. Liu,et al.  Structure of p300 bound to MEF2 on DNA reveals a mechanism of enhanceosome assembly , 2011, Nucleic acids research.

[53]  J. Rizo,et al.  The Mad2 spindle checkpoint protein has two distinct natively folded states , 2004, Nature Structural &Molecular Biology.

[54]  C. Anfinsen Principles that govern the folding of protein chains. , 1973, Science.

[55]  David Dunson,et al.  Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[56]  G. Lyons,et al.  Characterization of myocyte enhancer factor 2 (MEF2) expression in B and T cells: MEF2C is a B cell-restricted transcription factor in lymphocytes. , 1998, Molecular immunology.

[57]  R. Epand,et al.  Fusion peptides and the mechanism of viral fusion. , 2003, Biochimica et biophysica acta.

[58]  T. Richmond,et al.  Crystal structure of MEF2A core bound to DNA at 1.5 A resolution. , 2000, Journal of molecular biology.

[59]  Ryan D. Morin,et al.  Theoretical Investigation of the D83V Mutation within the Myocyte-Specific Enhancer Factor-2 Beta and Its Role in Cancer , 2013 .

[60]  D. Thirumalai,et al.  Exploring the propensities of helices in PrP(C) to form beta sheet using NMR structures and sequence alignments. , 2002, Biophysical journal.

[61]  A. Sharrocks,et al.  The MADS-box family of transcription factors. , 1995, European journal of biochemistry.

[62]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[63]  L. Kedes,et al.  Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C , 1997, Molecular and cellular biology.

[64]  O. Ornatsky,et al.  MEF2 Protein Expression, DNA Binding Specificity and Complex Composition, and Transcriptional Activity in Muscle and Non-muscle Cells* , 1996, The Journal of Biological Chemistry.

[65]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[66]  M. Marra,et al.  MEF2 transcription factors: developmental regulators and emerging cancer genes , 2015, Oncotarget.

[67]  N. Pannu,et al.  REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.

[68]  P. Harrison,et al.  Discordant and chameleon sequences: Their distribution and implications for amyloidogenicity , 2011, Protein science : a publication of the Protein Society.

[69]  T. Richmond,et al.  The B‐box dominates SAP‐1–SRF interactions in the structure of the ternary complex , 2001, The EMBO journal.

[70]  Lisa N Kinch,et al.  ChSeq: A database of chameleon sequences , 2015, Protein science : a publication of the Protein Society.

[71]  N. Jayathilaka,et al.  Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2 , 2012, Nucleic acids research.

[72]  A. Verdel,et al.  mHDA1/HDAC5 Histone Deacetylase Interacts with and Represses MEF2A Transcriptional Activity* , 2000, The Journal of Biological Chemistry.

[73]  G M Clore,et al.  Solution structure of the MEF2A–DNA complex: structural basis for the modulation of DNA bending and specificity by MADS‐box transcription factors , 2000, The EMBO journal.

[74]  Owen Johnson,et al.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM , 2011, Acta crystallographica. Section D, Biological crystallography.

[75]  Jun O. Liu,et al.  Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. , 2004, Journal of molecular biology.

[76]  Steven W. Flavell,et al.  Activity-Dependent Regulation of MEF2 Transcription Factors Suppresses Excitatory Synapse Number , 2006, Science.

[77]  H. Arnold,et al.  The myogenin gene is activated during myocyte differentiation by pre-existing, not newly synthesized transcription factor MEF-2. , 1994, The Journal of biological chemistry.

[78]  J. Skehel,et al.  Structure of influenza haemagglutinin at the pH of membrane fusion , 1994, Nature.

[79]  Michael P. Eichenlaub,et al.  A temporal map of transcription factor activity: mef2 directly regulates target genes at all stages of muscle development. , 2006, Developmental cell.

[80]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[81]  D Baker,et al.  The sequences of small proteins are not extensively optimized for rapid folding by natural selection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[82]  D. Figeys,et al.  Skeletal myosin light chain kinase regulates skeletal myogenesis by phosphorylation of MEF2C , 2011, The EMBO journal.

[83]  D. Dunson,et al.  Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.

[84]  F. Dequiedt,et al.  Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.

[85]  P. S. Kim,et al.  Context is a major determinant of β-sheet propensity , 1994, Nature.